PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Necroptosis in cancer: An angel or a demon?

Abstract In the past few decades, apoptosis has been regarded as the only form of programmed cell death. However, the traditional view has been challenged by the identification of several forms of regulated necrosis, including necroptosis. Necroptosis is typified by a necrotic cell death morphology and is controlled by RIP1, RIP3, and mixed lineage kinase domain-like protein. The physiological role of necroptosis is to serve as a "fail-safe" form of cell death for cells that fail to undergo apoptosis during embryonic development and disease defense. Currently, established studies have indicated that necroptosis is involved in cancer initiation and progression. Although elevated necroptosis contributes to cancer cell death, extensive cell death also increases the risk of proliferation and metastasis of the surviving cells by inducing the generation reactive oxygen species, activation of inflammation, and suppression of the immune response. Thus, questions regarding the overall impact of necroptosis on cancer remain open. In this review, we introduce the basic knowledge regarding necroptosis, summarize its dual effects on cancer progression, and analyze its advantages and disadvantages in clinical applications.
PMID
Related Publications

Necroptosis: is there a role for mitochondria?

The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.

Connections between various trigger factors and the RIP1/ RIP3 signaling pathway involved in necroptosis.

Necroptosis: an alternative cell death program defending against cancer.

Necroptosis in health and diseases.

Authors

Mayor MeshTerms
Keywords

Cancer progression

chemotherapy

metastasis

proliferation

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28651499
OWN - NLM
STAT- In-Process
DA  - 20170627
LR  - 20170627
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Necroptosis in cancer: An angel or a demon?
PG  - 1010428317711539
LID - 10.1177/1010428317711539 [doi]
AB  - In the past few decades, apoptosis has been regarded as the only form of
      programmed cell death. However, the traditional view has been challenged by the
      identification of several forms of regulated necrosis, including necroptosis.
      Necroptosis is typified by a necrotic cell death morphology and is controlled by 
      RIP1, RIP3, and mixed lineage kinase domain-like protein. The physiological role 
      of necroptosis is to serve as a "fail-safe" form of cell death for cells that
      fail to undergo apoptosis during embryonic development and disease defense.
      Currently, established studies have indicated that necroptosis is involved in
      cancer initiation and progression. Although elevated necroptosis contributes to
      cancer cell death, extensive cell death also increases the risk of proliferation 
      and metastasis of the surviving cells by inducing the generation reactive oxygen 
      species, activation of inflammation, and suppression of the immune response.
      Thus, questions regarding the overall impact of necroptosis on cancer remain
      open. In this review, we introduce the basic knowledge regarding necroptosis,
      summarize its dual effects on cancer progression, and analyze its advantages and 
      disadvantages in clinical applications.
FAU - Wang, Tianzhen
AU  - Wang T
AD  - 1 Department of Pathology, Harbin Medical University, Harbin, China.
FAU - Jin, Yinji
AU  - Jin Y
AD  - 1 Department of Pathology, Harbin Medical University, Harbin, China.
FAU - Yang, Weiwei
AU  - Yang W
AD  - 1 Department of Pathology, Harbin Medical University, Harbin, China.
FAU - Zhang, Lei
AU  - Zhang L
AD  - 1 Department of Pathology, Harbin Medical University, Harbin, China.
FAU - Jin, Xiaoming
AU  - Jin X
AD  - 1 Department of Pathology, Harbin Medical University, Harbin, China.
FAU - Liu, Xi
AU  - Liu X
AD  - 2 Department of Cardiovascular, Inner Mongolia People's Hospital, Hohhot, China.
FAU - He, Yan
AU  - He Y
AD  - 1 Department of Pathology, Harbin Medical University, Harbin, China.
FAU - Li, Xiaobo
AU  - Li X
AD  - 1 Department of Pathology, Harbin Medical University, Harbin, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
OTO - NOTNLM
OT  - Cancer progression
OT  - chemotherapy
OT  - metastasis
OT  - proliferation
EDAT- 2017/06/28 06:00
MHDA- 2017/06/28 06:00
CRDT- 2017/06/28 06:00
AID - 10.1177/1010428317711539 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317711539. doi: 10.1177/1010428317711539.